Philip Morris Transformation Accelerates With IQOS and ZYN Growth

Philip Morris International's Q2 2025 results highlight the accelerating success of its smoke-free transformation, with shipments up 11.8% driving a 15.2% revenue increase and 23.3% gross profit growth. Led by IQOS and ZYN, these higher-margin products now constitute 41% of total revenues and 42% of gross profit, effectively mitigating a 1.5% decline in cigarette volumes and demonstrating the company's ability to pivot towards sustainable, profitable growth.

Analysis

Philip Morris International's (PM) second-quarter 2025 results provide strong evidence that its strategic pivot to smoke-free products is successfully driving growth and profitability, effectively offsetting secular declines in its legacy combustible business. The smoke-free segment, led by IQOS and ZYN, delivered an 11.8% increase in shipment volumes, which translated into a 15.2% rise in net revenues and a significant 23.3% expansion in gross profit. This performance underscores the superior margin profile of these next-generation products, which now constitute a material 41% of total company revenues and 42% of gross profit. While traditional cigarette shipments contracted by 1.5%, the segment still generated $6 billion in revenue, a 2.1% year-over-year increase, indicating resilient pricing power that continues to fund the transition. Management's full-year guidance, projecting 12-14% smoke-free volume growth against a modest 2% decline in cigarette volumes, reinforces this positive trajectory. However, the company's stock trades at a premium forward P/E of 20.7x, well above the industry average of 15.69x, and has underperformed the industry by 5.2 percentage points in the last month, suggesting that high growth expectations are already priced in.

Key Decisions for Investors

• Investors should assess Philip Morris based on its demonstrated ability to execute its smoke-free transition, as the segment's high-margin growth is fundamentally altering the company's financial profile from a declining legacy business to a growth-oriented one.
• Given the stock's premium valuation at a 20.7x forward P/E, consider whether the consensus earnings growth estimates of 14.2% for 2025 and 11.9% for 2026 sufficiently justify the current price, especially in light of recent share underperformance relative to the industry.
• Monitor the rate of decline in combustible cigarette volumes, as this segment remains a critical source of cash flow; an acceleration in its decay could pressure the company's ability to fund its smoke-free expansion and shareholder returns.
• Closely track the competitive dynamics in the nicotine pouch and modern oral categories, where rivals like Altria and Turning Point Brands are demonstrating aggressive growth, which could challenge PM's market share and margin leadership in the future.